Health Care [ 12/12 ] | Biotechnology [ 58/74 ]
NASDAQ | Common Stock
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
Its lead product candidate, ciltacabtagene autoleucel, or cilta-cel, is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer.
In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China.
The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, and a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3.
The company was founded in 2014 and is headquartered in Somerset, New Jersey.
Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 10, 25 | 0.14 Increased by +117.50% | -0.38 Increased by +137.24% |
| Nov 12, 24 | -0.68 Decreased by -101.12% | -0.42 Decreased by -62.81% |
| Aug 9, 24 | -0.10 Increased by +91.23% | -0.38 Increased by +73.68% |
| May 13, 24 | -0.16 Increased by +76.47% | -0.34 Increased by +52.94% |
| Mar 11, 24 | -0.80 Decreased by -29.03% | -0.83 Increased by +3.61% |
| Nov 20, 23 | -0.34 Increased by +8.11% | -0.68 Increased by +50.00% |
| Aug 15, 23 | -1.14 Decreased by -245.45% | -0.60 Decreased by -90.00% |
| May 18, 23 | -0.68 Decreased by -161.54% | -0.78 Increased by +12.82% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 186.52 M Increased by +134.73% | 26.28 M Increased by +118.15% | Increased by +14.09% Increased by +107.73% |
| Sep 30, 24 | 160.21 M Increased by +66.86% | -125.32 M Decreased by -101.46% | Decreased by -78.23% Decreased by -20.74% |
| Jun 30, 24 | 186.52 M Increased by +154.36% | -18.20 M Increased by +90.86% | Decreased by -9.76% Increased by +96.41% |
| Mar 31, 24 | 93.99 M Increased by +28.18% | -59.79 M Increased by +69.97% | Decreased by -63.62% Increased by +76.57% |
| Dec 31, 23 | 79.46 M Increased by +118.69% | -144.82 M Decreased by -29.19% | Decreased by -182.24% Increased by +40.93% |
| Sep 30, 23 | 96.01 M Increased by +250.91% | -62.21 M Increased by +26.78% | Decreased by -64.79% Increased by +79.13% |
| Jun 30, 23 | 73.33 M Increased by +512.56% | -199.13 M Decreased by -3.05% | Decreased by -271.55% Increased by +83.18% |
| Mar 31, 23 | 73.33 M Increased by +512.56% | -199.13 M Decreased by -3.05% | Decreased by -271.55% Increased by +83.18% |